These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 38637137)
1. Development of a Visually Calculated SUV Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L J Nucl Med; 2024 Jun; 65(6):904-908. PubMed ID: 38637137 [No Abstract] [Full Text] [Related]
2. Quantitative Kuo PH; Morris MJ; Hesterman J; Kendi AT; Rahbar K; Wei XX; Fang B; Adra N; Garje R; Michalski JM; Chi K; de Bono J; Fizazi K; Krause B; Sartor O; Tagawa ST; Ghebremariam S; Brackman M; Wong CC; Catafau AM; Benson T; Armstrong AJ; Herrmann K Radiology; 2024 Aug; 312(2):e233460. PubMed ID: 39162634 [TBL] [Abstract][Full Text] [Related]
3. The Prognostic Value of Posttreatment Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906 [No Abstract] [Full Text] [Related]
4. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [ Song H; Leonio MI; Ferri V; Duan H; Aparici CM; Davidzon G; Franc BL; Moradi F; Shah J; Bergstrom CP; Fan AC; Shah S; Khaki AR; Srinivas S; Iagaru A Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2784-2793. PubMed ID: 38635050 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L J Nucl Med; 2023 Feb; 64(2):221-226. PubMed ID: 36008120 [No Abstract] [Full Text] [Related]
6. Early response monitoring during [ Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A; Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755 [TBL] [Abstract][Full Text] [Related]
7. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [ Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger IA; Eiber M; Emmett L; Farolfi A; Fendler WP; Weber MM; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J J Nucl Med; 2023 Jul; 64(7):1024-1029. PubMed ID: 36997329 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Performance of RECIP 1.0 Based on [ Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363 [TBL] [Abstract][Full Text] [Related]
13. Results of a Prospective Phase 2 Pilot Trial of Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival. Kurth J; Kretzschmar J; Aladwan H; Heuschkel M; Gummesson A; Bergner C; Kundt G; Hakenberg OW; Krause BJ; Schwarzenböck SM Nucl Med Commun; 2021 Nov; 42(11):1217-1226. PubMed ID: 34424870 [TBL] [Abstract][Full Text] [Related]
15. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746 [TBL] [Abstract][Full Text] [Related]
16. RECIP 1.0 Predicts Progression-Free Survival After [ Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Solnes LB; Calais J; Rettig MB; Weber M; Farolfi A; Benz MR; Eiber M J Nucl Med; 2024 Jun; 65(6):917-922. PubMed ID: 38637143 [TBL] [Abstract][Full Text] [Related]
17. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer. Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963 [TBL] [Abstract][Full Text] [Related]